Journal
CANCER TREATMENT REVIEWS
Volume 33, Issue 3, Pages 299-313Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2006.12.005
Keywords
bevacizumab; renal cell carcinoma; sorafenib; sunitinib; targeted therapy; temsirolimus
Categories
Funding
- NCI NIH HHS [N01 CM17101] Funding Source: Medline
Ask authors/readers for more resources
Renal cell carcinoma (RCC) accounts for about 3% of all adult malignancies and its incidence is increasing. Smoking, obesity, and end-stage renal disease are important risk factors. Localized RCC may be cured with surgical excision. However, over one-third of patients eventually develop metastatic disease. White chemotherapy and radiation therapy are relatively ineffective for RCC, immunotherapy modestly extends survival and may lead to tumor regression and tong-term survival in a small minority of patients. Recently, research into the pathology of genetic syndromes associated with RCC has led to remarkable advances in our understanding of the pathogenesis of sporadic RCC. Rational therapeutic agents developed from this understanding have established new treatment paradigms for this disease. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available